Table 2.

Characteristics of bismuth- or PPI-based quadruple therapies.

Refs	Combination regimens	Dose	Treatment duration	Eradication rate (ITT)		P
				PUD	NUD
				N/T.N (%)	N/T.N (%)
17	CBS/Met/Tet/Lan	120 mg ×8/250 mg ×8/250 mg ×8/30 mg b.i.d.	1d	22/33 (66.7)	5/13 (38.5)	0.16
17	CBS/Met/Tet/Lan	120 mg ×8/250 mg ×8/250 mg ×8/30 mg b.i.d.	2 d	26/35 (74.3)	20/40 (50)	0.06
13	Amo/Cla/Tin/Ome	1 g b.i.d./500 mg b.i.d./500 mg b.i.d./20 mg b.i.d.	5 d12	30/31 (96.8)	31/34 (91.2)	0.68
18	Bis/Met/Tet/Lan	120 mg q.i.d./400 mg t.i.d./500 mg q.i.d./30 mg q.d.	7 d	91/101 (90.1)	107/118 (90.7)	0.93
19	Bis/Met/Tet/Ome	120 mg q.i.d./400 mg t.i.d./500 mg q.i.d./30 mg q.d.	10 d	53/57 (93)	46/49 (93.9)	0.84
8	Bis/Met/Tet/Ome	120 mg q.i.d./500 mg t.i.d./500 mg q.i.d./20 mg b.i.d.	14 d	9/11 (81.8)	8/13 (61.5)	0.53

CBS, colloidal bismuth subcitrate; Met, metronidazole; Tet, tetracycline; Lan, lansoprazole; Bis, bismuth; Cla, clarithromycin; Rab, rabeprazole; Tin, tinidazole; Amo, amoxicillin; ×8, 8 times daily; q.i.d., four times daily; q.d., once daily; b.i.d., twice daily; Ome, omeprazole.

¹Rabeprazole and amoxicillin were used on d 1-5, clarithromycin and tinidazole on d 6-10;

²amoxicillin was used on d 1-5, clarithromycin and tinidazole on d 6-10, and omeprazole on d 1-10. PUD, peptic ulcer disease; NUD, non-ulcer dyspepsia; N/T.N, number/total number.